Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.Y. Frolov
Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn90 - Cost-Effectiveness and Budget Impact Analysis of Nilotinib for the Second Line Tratment of Chronic Mieloid Leukemia in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer
FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
Breast Care
Surgery
Oncology
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?
Future Medicinal Chemistry
Drug Discovery
Molecular Medicine
Pharmacology
CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer
Cancer Cell
Cancer Research
Oncology
Cell Biology
Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer
npj Breast Cancer
Oncology
Radiology
Nuclear Medicine
Pharmacology
Imaging
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Treating ER+ Breast Cancer With CDK4/6 Inhibitors
Cancer Discovery
Oncology
